Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 18042454
Rocques N, et al. (2007) GSK-3-mediated phosphorylation enhances Maf-transforming activity. Mol Cell 28, 584-97 18042454
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S49-p - MAFA (human)
Modsite: CHRLPPGsLSStPLS SwissProt Entrez-Gene
Orthologous residues
MAFA (human): S49‑p, MAFA (mouse): S49‑p, MAFA (quail): S49‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site, phosphopeptide mapping
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  CEF, HEK293T (epithelial), INS-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  chicken, human, rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GSK3B (human) siRNA inhibition of enzyme, inhibition of upstream enzyme, pharmacological inhibitor of upstream enzyme
KINASE GSK3A (human) siRNA inhibition of enzyme, inhibition of upstream enzyme, pharmacological inhibitor of upstream enzyme
Downstream Regulation
Effect of modification (function):  molecular association, regulation, protein degradation, ubiquitination
Effect of modification (process):  carcinogenesis, induced, transcription, induced
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
PCAF (human) Induces co-immunoprecipitation

T53-p - MAFA (human)
Modsite: PPGsLSStPLStPCS SwissProt Entrez-Gene
Orthologous residues
MAFA (human): T53‑p, MAFA (mouse): T53‑p, MAFA (quail): T53‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, phosphopeptide mapping, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  CEF, HEK293T (epithelial), INS-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  chicken, human, rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GSK3A (human) siRNA inhibition of enzyme, inhibition of upstream enzyme, pharmacological inhibitor of upstream enzyme
KINASE GSK3B (human) siRNA inhibition of enzyme, inhibition of upstream enzyme, pharmacological inhibitor of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
lithium decrease
1-azakenpaullone decrease
U0126 no change compared to control
seliciclib no change compared to control
Downstream Regulation
Effect of modification (function):  molecular association, regulation, protein degradation, ubiquitination
Effect of modification (process):  carcinogenesis, induced, transcription, induced
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
PCAF (human) Induces co-immunoprecipitation

T57-p - MAFA (human)
Modsite: LSStPLStPCSsVPS SwissProt Entrez-Gene
Orthologous residues
MAFA (human): T57‑p, MAFA (mouse): T57‑p, MAFA (quail): T57‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site, phospho-antibody, phosphopeptide mapping, western blotting
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  CEF, HEK293T (epithelial), INS-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  chicken, human, rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GSK3B (human) siRNA inhibition of enzyme, inhibition of upstream enzyme, pharmacological inhibitor of upstream enzyme
KINASE GSK3A (human) siRNA inhibition of enzyme, inhibition of upstream enzyme, pharmacological inhibitor of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
lithium decrease
1-azakenpaullone decrease
U0126 no change compared to control
seliciclib no change compared to control
Downstream Regulation
Effect of modification (function):  molecular association, regulation, protein degradation, ubiquitination
Effect of modification (process):  carcinogenesis, induced, transcription, induced
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
PCAF (human) Induces co-immunoprecipitation

S61-p - MAFA (human)
Modsite: PLStPCSsVPSsPSF SwissProt Entrez-Gene
Orthologous residues
MAFA (human): S61‑p, MAFA (mouse): S61‑p, MAFA (quail): S61‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site, phosphopeptide mapping
Disease tissue studied:  pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  CEF, HEK293T (epithelial), INS-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  chicken, human, rat
Enzymes shown to modify site in vitro
Type Enzyme
KINASE GSK3B (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE GSK3B (human) siRNA inhibition of enzyme, inhibition of upstream enzyme, pharmacological inhibitor of upstream enzyme
KINASE GSK3A (human) siRNA inhibition of enzyme, inhibition of upstream enzyme, pharmacological inhibitor of upstream enzyme
Downstream Regulation
Effect of modification (function):  molecular association, regulation, protein degradation, ubiquitination
Effect of modification (process):  carcinogenesis, induced, transcription, induced
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
PCAF (human) Induces co-immunoprecipitation